A Genetically Engineered Biofilm Material for SARS-CoV-2 Capturing and Isolation
© 2022 Wiley‐VCH GmbH..
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously infecting people all around the world since its outbreak in 2019. Studies for numerous infection detection strategies are continuing. The sensitivity of detection methods is crucial to separate people with mild infections from people who are asymptomatic. In this sense, a strategy that would help to capture and isolate the SARS-CoV-2 virus prior to tests can be effective and beneficial. To this extent, genetically engineered biomaterials grounding from the biofilm protein of Escherichia coli are beneficial due to their robustness and adaptability to various application areas. Through functionalizing the E. coli biofilm protein, diverse properties can be attained such as enzyme display, nanoparticle production, and medical implant structures. Here, E. coli species are employed to express major curli protein CsgA and Griffithsin (GRFT) as fusion proteins, through a complex formation using SpyTag and SpyCatcher domains. In this study, a complex system with a CsgA scaffold harboring the affinity of GRFT against Spike protein to capture and isolate SARS-CoV-2 virus is successfully developed. It is shown that the hybrid recombinant protein can dramatically increase the sensitivity of currently available lateral flow assays for Sars-CoV-2 diagnostics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Advanced materials interfaces - (2022) vom: 13. Sept., Seite 2201126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Özkul, Gökçe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Concentrating |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/admi.202201126 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347632793 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347632793 | ||
| 003 | DE-627 | ||
| 005 | 20240217232125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/admi.202201126 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM347632793 | ||
| 035 | |a (NLM)36248312 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Özkul, Gökçe |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Genetically Engineered Biofilm Material for SARS-CoV-2 Capturing and Isolation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2022 Wiley‐VCH GmbH. | ||
| 520 | |a The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously infecting people all around the world since its outbreak in 2019. Studies for numerous infection detection strategies are continuing. The sensitivity of detection methods is crucial to separate people with mild infections from people who are asymptomatic. In this sense, a strategy that would help to capture and isolate the SARS-CoV-2 virus prior to tests can be effective and beneficial. To this extent, genetically engineered biomaterials grounding from the biofilm protein of Escherichia coli are beneficial due to their robustness and adaptability to various application areas. Through functionalizing the E. coli biofilm protein, diverse properties can be attained such as enzyme display, nanoparticle production, and medical implant structures. Here, E. coli species are employed to express major curli protein CsgA and Griffithsin (GRFT) as fusion proteins, through a complex formation using SpyTag and SpyCatcher domains. In this study, a complex system with a CsgA scaffold harboring the affinity of GRFT against Spike protein to capture and isolate SARS-CoV-2 virus is successfully developed. It is shown that the hybrid recombinant protein can dramatically increase the sensitivity of currently available lateral flow assays for Sars-CoV-2 diagnostics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a concentrating | |
| 650 | 4 | |a genetically engineered biomaterials | |
| 650 | 4 | |a virus capturing | |
| 700 | 1 | |a Kehribar, Ebru Şahin |e verfasserin |4 aut | |
| 700 | 1 | |a Ahan, Recep Erdem |e verfasserin |4 aut | |
| 700 | 1 | |a Köksaldı, İlkay Çisil |e verfasserin |4 aut | |
| 700 | 1 | |a Özkul, Aykut |e verfasserin |4 aut | |
| 700 | 1 | |a Dinç, Bedia |e verfasserin |4 aut | |
| 700 | 1 | |a Aydoğan, Sibel |e verfasserin |4 aut | |
| 700 | 1 | |a Şeker, Urartu Özgür Şafak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced materials interfaces |d 2014 |g (2022) vom: 13. Sept., Seite 2201126 |w (DE-627)NLM24438116X |x 2196-7350 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:13 |g month:09 |g pages:2201126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/admi.202201126 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 13 |c 09 |h 2201126 | ||